2017
Chapter 2 The Cellular Mechanisms of Executive Functions and Working Memory Relevance to Mental Disorders
Lightbourne T, Arnsten A. Chapter 2 The Cellular Mechanisms of Executive Functions and Working Memory Relevance to Mental Disorders. 2017, 21-40. DOI: 10.1016/b978-0-12-803676-1.00002-7.Peer-Reviewed Original ResearchPrefrontal cortexAttention deficit hyperactivity disorderDevastating neuropsychiatric disorderAdvanced ageTopographical organizationTherapeutic interventionsAlzheimer's diseaseMental disordersBrain regionsNeuropsychiatric pathologiesNormal individualsHigher-order cognitive abilitiesNeuropsychiatric disordersUncontrollable stressHyperactivity disorderCellular mechanisms
2015
Catecholamine mechanisms in the prefrontal cortex: proven strategies for enhancing higher cognitive function
Berridge C, Arnsten A. Catecholamine mechanisms in the prefrontal cortex: proven strategies for enhancing higher cognitive function. Current Opinion In Behavioral Sciences 2015, 4: 33-40. DOI: 10.1016/j.cobeha.2015.01.002.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderPharmacological treatmentCognitive dysfunctionPrefrontal cognitive dysfunctionCognition-enhancing effectsMultiple psychiatric disordersSpecific intracellular pathwaysDeficit hyperactivity disorderPrefrontal catecholaminesClinical efficacyCatecholamine mechanismsADHD medicationNovel medicationsReceptor mechanismsPrefrontal cognitionPsychiatric disordersCatecholamine receptorsCatecholamine modulationHigher cognitive functionsCognitive functionPrefrontal cortexHyperactivity disorderImproved treatmentIntracellular pathwaysKey modulator
2014
Catecholamine influences on prefrontal cortex circuits and function
Arnsten A, Berridge C. Catecholamine influences on prefrontal cortex circuits and function. 2014, 161-173. DOI: 10.1017/cbo9781139035491.015.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderHyperactivity disorderManagement of ADHDDiagnosis of ADHDChronic neurobehavioral disorderPrefrontal cortex circuitCatecholamine influenceCortex circuitTreatment modalitiesPsychiatric illnessNeurobehavioral disordersClinical optionBipolar disorderSocial workersDisordersRecent researchDiagnosisAdultsChildrenDevelopmental processesDistractibilityImpulsivityPsychologistsComorbiditiesWorld-renowned experts
2012
Attention deficit hyperactivity disorder
Berridge C, Devilbiss D, Spencer R, Schmeichel B, Arnsten A. Attention deficit hyperactivity disorder. 2012, 303-320. DOI: 10.1017/cbo9780511980053.018.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderHyperactivity disorderNeurodevelopmental disordersMore effective treatmentsMultiple sclerosisDisease groupEffective treatmentParkinson's diseaseBipolar disorderBrain disordersAlzheimer's diseaseClinical advancementTranslational neuroscienceSubstance abuseDiseaseDisordersField of psychiatryPublic healthCliniciansNeurologyPsychiatryPainSclerosisEpilepsyGuanfacine for the treatment of cognitive disorders: a century of discoveries at Yale.
Arnsten AF, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. The Yale Journal Of Biology And Medicine 2012, 85: 45-58. PMID: 22461743, PMCID: PMC3313539.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderPrefrontal cortexCognitive disordersHigher-order cognitive abilitiesDeficit hyperactivity disorderPFC cognitive functionCognitive abilitiesHyperactivity disorderCognitive functionMemory functionPFC functionAgonist guanfacineBrain regionsGuanfacineRecent researchNeurobiologyYale Medical SchoolCentury of discoveryDisordersTherapeutic targetTourette syndromePostsynaptic spinesEmotionsMemorySyndrome
2005
Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder
Arnsten A. Chapter 11 Molecular Pharmacology and the Treatment of Tourette's Syndrome and Attention Deficit-Hyperactivity Disorder. 2005, 183-iv. DOI: 10.1016/b978-012738903-5/50012-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderDeficit hyperactivity disorderPrefrontal cortexTourette syndromeTherapeutic actionUse of guanfacineΑ2-adrenoceptor agonistNeuropsychiatric symptomsAppropriate medicationNeuromodulatory effectsTourette patientsPostsynaptic sitesNeurochemical environmentNeuropsychiatric illnessBrain circuitsSyndromePFC regulationBasic neuroscienceMolecular pharmacologyMolecular targetsDisordersGuanfacinePatientsPFC functionTreatment
1998
Catecholamine modulation of prefrontal cortical cognitive function
Arnsten A. Catecholamine modulation of prefrontal cortical cognitive function. Trends In Cognitive Sciences 1998, 2: 436-447. PMID: 21227275, DOI: 10.1016/s1364-6613(98)01240-6.Peer-Reviewed Original ResearchAttention deficit hyperactivity disorderPrefrontal cortexCognitive functionPrefrontal cortical cognitive functionUncontrollable stressCortical cognitive functionsWorking Memory FunctionDeficit hyperactivity disorderHyperactivity disorderPFC functionPFC dysfunctionNormal agingCognitive disordersCatecholamine modulationDopamine systemNeurochemical influencesMental disordersNeuropsychiatric disordersDisordersEnvironmental cuesCuesNeuromodulatory inputsMemoryFresh understandingHigh levels
1997
Noradrenergic Influences on Prefrontal Cortical Cognitive Function: Opposing Actions at Postjunctional α1 Versus α2-Adrenergic Receptors
Arnsten A, Steere JC, Jentsch DJ, Li BM. Noradrenergic Influences on Prefrontal Cortical Cognitive Function: Opposing Actions at Postjunctional α1 Versus α2-Adrenergic Receptors. Advances In Pharmacology 1997, 42: 764-767. PMID: 9328010, DOI: 10.1016/s1054-3589(08)60859-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPrefrontal cortexNE releaseΑ2 receptorsCognitive impairmentBeneficial effectsPFC functionBasal NE releasePrefrontal cortical cognitive functionΑ2-adrenergic receptorsCortical cognitive functionsPotential cognitive enhancersAttention deficit hyperactivity disorderMemory functionDeficit hyperactivity disorderPostsynaptic α1Α1d subtypesNE terminalsΑ-adrenoceptorsΑ2 agonistsLithium medicationNoradrenergic influenceOpen trialLithium pretreatmentΑ2A subtypeΑ2A receptors
1995
Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience
CHAPPELL P, RIDDLE M, SCAHILL L, LYNCH K, SCHULTZ R, ARNSTEN A, LECKMAN J, COHEN D. Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience. Journal Of The American Academy Of Child & Adolescent Psychiatry 1995, 34: 1140-1146. PMID: 7559307, DOI: 10.1097/00004583-199509000-00010.Peer-Reviewed Original ResearchConceptsYale Global Tic Severity ScaleAttention deficit hyperactivity disorderTourette syndromeContinuous Performance TestHyperactivity disorderOpen-label studyCommon side effectsSeverity of motorComorbid attention deficit hyperactivity disorderSafe alternative therapySignificant decreaseTic Severity ScalePreliminary clinical experienceMajority of subjectsConners' Parent Rating ScaleTransient sedationControlled TrialsAlternative therapiesSedative effectsGuanfacine treatmentPhonic ticsSeverity ScaleSide effectsStimulant medicationTic severityAn Open Trial of Guanfacine in the Treatment of Attention-Deficit Hyperactivity Disorder
Hunt R, Arnsten A, Asbell M. An Open Trial of Guanfacine in the Treatment of Attention-Deficit Hyperactivity Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 1995, 34: 50-54. PMID: 7860456, DOI: 10.1097/00004583-199501000-00013.Peer-Reviewed Original ResearchConceptsAttention deficit hyperactivity disorderGreater attentional abilityConners' Parent RatingUse of guanfacineAttentional abilitiesConners' hyperactivityParent ratingsHyperactivity disorderFrustration tolerancePatients' mean scoresSelective binding profileHyperactive childrenLonger excretionGuanfacine treatmentADHDHyperactive behaviorMean scoreSide effectsAlpha-2 noradrenergic agonistPsychiatric outpatientsGuanfacineDouble-blind studyBehavioral changesSedative side effectsOpen trial